ArticleMikrochimica acta2026
Machine-learning-integrated NLRC3 and cardiac troponin T dual-analyte lateral-flow biosensor for point-of-care acute coronary syndrome screening and acute myocardial infarction-unstable angina discrimination.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The implementation of high-sensitivity cardiac troponin assays has significantly improved the prompt diagnosis of acute myocardial infarction (AMI). Nevertheless, early risk stratification and the swift diagnosis of acute coronary syndromes (ACS) remain challenging. We report a machine-learning-integrated NLRC3/cTnT dual-analyte time-resolved fluorescent lateral-flow immunoassay biosensor for quantitative ACS screening and discrimination of acute myocardial infarction (AMI) from unstable angina (UA). The biosensor uses europium nanoparticle time-resolved fluorescence in a dual-channel lateral-flow setup to simultaneously detect NLRC3 and cTnT within 20 min. The original serum sample is diluted separately for each channel, with 100 µL of the diluted sample applied to each. The optimized NLRC3 and cTnT assays demonstrated strong quantitative performance, precision, minimal cross-reactivity, and acceptable interference resistance. In clinical evaluation, NLRC3 alone identified ACS with 80.5% accuracy but was less effective in distinguishing AMI-UA. By combining NLRC3 and cTnT using a Naïve Bayes classifier, the dual-analyte biosensor improved to 84.6% sensitivity, 89.6% specificity, and 87.8% accuracy for AMI-UA discrimination. This study introduces a dual-pathophysiology lateral-flow biosensor that merges inflammatory-risk and myocardial-injury detection, providing a practical POCT method for decentralized ACS triage.
Indexed as
Identifiers
42911429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.